South Korea’s Mirae Asset Venture Investment has co-led an $18 million investment in KAHR Medical Ltd., an Israeli biopharmaceutical company that claims to be developing a novel drug platform based on bi-functional, immunotherapeutic fusion proteins, according to an announcement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
